Solventum is scheduled to release second-quarter 2026 results on August 5 after market close. The Zacks Consensus Estimate for revenues is $2.17 billion and for earnings is $1.91 per share. Reported revenues are expected to have benefited from more than $100 million of advanced customer orders ahead of the planned U.S. ERP cutover in the third quarter, though management noted this represents a timing shift rather than incremental demand, with the benefit expected to reverse mainly in the third quarter. The MedSurg segment is likely to have been driven by Advanced Wound Care and the Acera acquisition, while Dental Solutions and Health Information Systems are also expected to have performed solidly. Tariff-related headwinds are expected to remain a drag, but savings from the Transform for the Future program and other productivity initiatives are likely to have supported margin expansion. Zacks does not predict an earnings beat this quarter, as the Earnings ESP is 0.00% despite a Zacks Rank of 2.
Cardinal Health Inc
Cencora Inc.Solventum Corp.Q2 earnings report with mixed factors: advanced orders boost revenue but are timing shift, tariff headwinds, and productivity savings.
Agilent Technologies Inc